How to continue Strattera after moving to New York

If you’re struggling with ADHD and wondering whether you can access non-stimulant medications like Strattera through telehealth, you’re not alone. Millions of Americans are turning to virtual care for mental health treatment, but navigating the patchwork of federal and state regulations can feel overwhelming—especially when it comes to ADHD medications.

The short answer: Yes, you can get ADHD non-stimulant medications prescribed via telehealth in all 50 states. Because medications like Strattera (atomoxetine) are not controlled substances, they aren’t subject to the strict federal prescribing rules that govern stimulant medications. This makes telehealth a convenient, accessible option for many people seeking treatment.

But as with most healthcare topics, the details matter. State laws vary, provider qualifications differ, and understanding your options can help you make informed decisions about your care. In this comprehensive guide, we’ll walk you through everything you need to know about getting ADHD non-stimulant medication through telehealth in 2025.

Understanding ADHD Non-Stimulant Medications

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications offer an alternative treatment path for ADHD that works differently than traditional stimulants like Adderall or Ritalin. The most commonly prescribed non-stimulant is Strattera (atomoxetine), which works by selectively inhibiting the reuptake of norepinephrine—a neurotransmitter that plays a key role in attention and impulse control.

Other non-stimulant options include:

• Intuniv (guanfacine)
• Kapvay (clonidine)
• Qelbree (viloxazine)

Why Choose a Non-Stimulant?

Non-stimulant medications can be an excellent choice for several reasons:

Medical considerations: Some people have conditions that make stimulants risky or inappropriate, such as uncontrolled high blood pressure, heart conditions, or a history of substance abuse.

Side effect profile: While stimulants can cause appetite suppression, sleep issues, or increased anxiety, non-stimulants typically have a different side effect profile that some patients tolerate better.

No controlled substance status: Strattera is not a DEA-controlled substance, which means no risk of dependency or abuse. This also translates to more flexible prescribing—your doctor can write prescriptions with refills for up to 90 days, making ongoing treatment more convenient.

Steady symptom control: Unlike stimulants that work immediately but wear off, Strattera builds up in your system over 4–6 weeks, providing consistent, round-the-clock symptom management without the peaks and valleys.

The Controlled vs. Non-Controlled Distinction

This distinction is crucial for understanding telehealth prescribing rules. The DEA classifies ADHD stimulants (Adderall, Ritalin, Vyvanse) as Schedule II controlled substances due to their potential for abuse. This triggers special federal rules under the Ryan Haight Act, which historically required an in-person medical exam before prescribing controlled substances online.

Strattera, however, is not a controlled substance. The FDA has determined it carries no significant abuse potential, so it’s exempt from these federal restrictions. This means telehealth providers can prescribe Strattera based on a comprehensive video evaluation alone—no in-person visit required by federal law.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

The Current Federal Landscape for Telehealth Prescribing

DEA Telehealth Flexibilities: Where We Stand in 2025

During the COVID-19 pandemic, the DEA implemented emergency flexibilities that allowed healthcare providers to prescribe controlled substances via telehealth without a prior in-person exam. These flexibilities have been extended multiple times—most recently through December 31, 2025.

This extension primarily impacts stimulant medications. For non-stimulants like Strattera, these temporary rules don’t really matter because there were never federal restrictions on tele-prescribing them in the first place.

What Happens After December 31, 2025?

The DEA is currently working on permanent regulations that may include a ‘special registration’ pathway for telehealth prescribing of controlled substances. However, as of late 2025, no final rule has been published. Industry experts anticipate either a fourth extension into 2026 or new regulations that could require at least one in-person visit within a certain timeframe for stimulant medications.

Important for patients: If you’re taking non-stimulant medication, these changes won’t directly affect you. However, if you’re taking or considering stimulant medication, stay in communication with your telehealth provider about any policy updates.

The Ryan Haight Act: Understanding the Foundation

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was designed to prevent illegal online pharmacies from dispensing controlled substances without proper medical oversight. It requires at least one in-person medical evaluation before prescribing controlled substances via telemedicine.

However, this law specifically exempts non-controlled medications. Since Strattera isn’t a controlled substance, the Ryan Haight Act’s in-person requirement simply doesn’t apply. Licensed providers can evaluate you via secure video and prescribe Strattera if clinically appropriate—no exceptions or special waivers needed.

State-by-State Telehealth Rules: What You Need to Know

While federal law sets the baseline, states can (and do) impose additional requirements for telehealth practice. Here’s what you need to know about key states:

California: Telehealth-Friendly with Modern Standards

California fully supports telehealth for ADHD treatment. The state doesn’t require an in-person exam for non-controlled medications—a comprehensive telehealth evaluation satisfies the ‘good faith exam’ standard of care.

Recent developments: California legislators proposed AB 1503 to further modernize tele-prescribing definitions and explicitly clarify that telehealth exams can establish a valid patient-provider relationship for prescribing. While still pending as of late 2025, this signals California’s commitment to accessible telehealth care.

Nurse practitioners in California gained independent practice authority through AB 890, allowing experienced NPs to evaluate and treat ADHD patients without physician oversight.

New York: Stricter Rules for Controlled Substances

New York reinstated an in-person requirement in May 2025—but only for controlled substances. If you’re seeking stimulant medication, New York law now requires an initial in-person medical evaluation before a provider can prescribe via telehealth.

However, this doesn’t affect Strattera or other non-stimulants. New York providers can prescribe non-controlled ADHD medications purely through telehealth without any in-person visit requirement.

Provider scope: New York NPs have independent practice authority and can prescribe ADHD medications, including controlled substances, after completing 3,600 hours of supervised practice.

Florida: Psychiatric Exception Makes ADHD Care Accessible

Florida has specific rules about telehealth prescribing of Schedule II controlled substances—generally prohibiting it except for psychiatric conditions, hospitalized patients, or those in hospice/nursing facilities.

Fortunately, ADHD is recognized as a psychiatric disorder, so Florida providers can prescribe stimulants via telehealth under this exception. For non-stimulants like Strattera, there are no special restrictions whatsoever.

Prescription monitoring: Florida requires providers to check the state’s Prescription Drug Monitoring Program (PDMP) before every controlled substance prescription. While this doesn’t apply to Strattera, your provider will likely still review your medication history as part of comprehensive care.

Advanced practice: Florida NPs and PAs practice under physician collaboration agreements. They can prescribe Schedule II medications with proper delegation, though NPs are limited to 7-day supplies of Schedule II drugs (except psychiatric NPs treating mental illness).

Texas: Mental Health Telehealth Supported

Texas has embraced telehealth for behavioral health services, including ADHD treatment. The state doesn’t require in-person visits for mental health care or non-controlled medication prescribing.

Important limitation: Texas restricts NP and PA authority to prescribe Schedule II stimulants to hospital or hospice settings only. If you’re seeing an NP or PA via telehealth in Texas, they can prescribe Strattera but would need physician involvement for stimulant medications.

Physicians licensed in Texas can prescribe both stimulants and non-stimulants via telehealth, making it important to understand your provider’s qualifications.

Alabama: Strict Rules with Mental Health Exceptions

Alabama maintains some of the nation’s strictest telehealth prescribing rules. Generally, after four telehealth visits for the same condition, patients must have an in-person visit within 12 months.

Key exception: Mental health services are exempt from this 12-month rule, which may cover psychiatric ADHD treatment. Even so, Alabama requires that for initial controlled substance prescriptions via telehealth, a licensed healthcare professional must be physically present with the patient.

These strict rules don’t apply to non-controlled medications like Strattera, but they illustrate Alabama’s cautious approach to telehealth.

New Hampshire: Recent Expansion of Access

New Hampshire made significant changes in August 2025 with SB 252, which explicitly allows telemedicine prescribing of Schedule II–IV controlled substances without an initial in-person exam.

The new law requires only that providers conduct a follow-up evaluation at least annually for ongoing controlled substance prescribing—and this can be done via telehealth.

For non-stimulant medications, New Hampshire has no special requirements beyond standard clinical practice.

Georgia: Following Federal Standards

Georgia doesn’t impose state-specific in-person requirements for telehealth prescribing beyond federal rules. Providers can prescribe non-controlled ADHD medications via comprehensive telehealth evaluation.

Provider limitations: Georgia NPs and PAs cannot prescribe Schedule II drugs (stimulants), even with physician collaboration. However, they can prescribe Schedule III–V medications and non-controlled drugs like Strattera under appropriate supervision.

PDMP requirements: Georgia requires checking the prescription monitoring database when first prescribing a controlled substance to a patient, then at least every 90 days for ongoing therapy.

Comparing Telehealth Medication Options: Stimulants vs. Non-Stimulants

Who Can Prescribe ADHD Medications via Telehealth?

Physicians (MD/DO)

Licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth in all states, provided they:

• Hold an active medical license in the patient’s state
• Maintain appropriate DEA registration (for controlled substances)
• Follow standard of care and state-specific telehealth requirements

Nurse Practitioners (NPs)

NP prescribing authority varies significantly by state:

Full practice authority states (including New York, Illinois, New Hampshire, California): NPs can independently diagnose ADHD and prescribe both controlled and non-controlled medications after meeting experience requirements (typically 2,000–4,000 supervised hours).

Reduced practice authority states (including Florida, Texas, Pennsylvania): NPs must maintain collaborative agreements with physicians. They can prescribe non-controlled medications like Strattera, but controlled substance prescribing may be limited:

• Texas: NPs cannot prescribe Schedule II stimulants in outpatient telehealth settings
• Florida: NPs can prescribe Schedule II but with 7-day supply limits (except psychiatric NPs)
• Pennsylvania: NPs can prescribe Schedule II with collaborative agreement, limited to 30-day initial supply

Restricted practice states (including Georgia, Alabama): NPs cannot prescribe Schedule II medications at all, even under physician supervision. They can prescribe Strattera and other non-controlled ADHD medications with appropriate collaboration.

Physician Assistants (PAs)

PAs practice under physician supervision in all states but can prescribe medications (including controlled substances) within their scope of practice as delegated by their supervising physician. The same state-by-state limitations that apply to NPs generally apply to PAs.

Psychiatrists and Psychiatric NPs

Board-certified psychiatrists and psychiatric nurse practitioners often have the most comprehensive authority and experience in treating ADHD. They’re typically well-versed in both medication management and psychotherapy approaches.

How Klarity Health Makes Telehealth ADHD Treatment Accessible

Klarity Health understands that navigating the complexities of telehealth ADHD care shouldn’t add to your stress. That’s why we’ve built a platform designed around your needs:

Licensed providers in your state: We match you with board-certified clinicians who are fully licensed in your state and understand local regulations. Whether you need a physician, psychiatrist, or psychiatric nurse practitioner, we ensure your provider has the appropriate credentials and DEA registration.

Transparent pricing: We accept both insurance and offer cash-pay options with clear, upfront pricing—no surprise bills or hidden fees.

Provider availability: Get appointments quickly, often within 48 hours, with flexible scheduling including evenings and weekends.

Comprehensive evaluations: Our providers conduct thorough ADHD assessments using DSM-5 criteria, not ‘quick consultations.’ We take the time to understand your symptoms, medical history, and treatment goals.

Coordinated care: We can work with your other healthcare providers and facilitate any necessary in-person evaluations or testing to ensure you receive comprehensive, safe treatment.

What to Expect from a Telehealth ADHD Evaluation

Before Your Appointment

Gather relevant information:

• Previous medical records, especially any prior ADHD evaluations or treatment
• Current medication list
• School records or report cards if you’re a young adult (symptoms must have started in childhood)
• Work performance reviews or feedback that might document attention issues

Complete screening questionnaires: Most telehealth providers will ask you to fill out validated ADHD rating scales (like the ASRS or Conners scales) before your appointment.

Prepare your medical history: Be ready to discuss:

• Current symptoms and how they impact your daily life
• When symptoms first started
• Previous treatments tried
• Any mental health conditions (depression, anxiety, etc.)
• Family history of ADHD
• Substance use history
• Current medical conditions and medications

During the Video Visit

A comprehensive ADHD telehealth evaluation typically takes 45–60 minutes and includes:

Symptom assessment: Your provider will ask detailed questions about inattention, hyperactivity, and impulsivity symptoms in multiple settings (home, work, school, relationships).

Diagnostic criteria review: They’ll systematically go through DSM-5 criteria to determine if you meet the threshold for an ADHD diagnosis.

Differential diagnosis: Good clinicians rule out other conditions that can mimic ADHD, such as anxiety, depression, sleep disorders, or thyroid problems.

Treatment discussion: If ADHD is diagnosed, your provider will discuss treatment options—both medication and non-medication approaches. For medication, they’ll explain the differences between stimulants and non-stimulants, helping you make an informed choice.

Safety screening: They’ll review contraindications to ensure any prescribed medication is safe for you, checking for heart conditions, glaucoma, recent MAOI use, liver problems, etc.

What Happens After Diagnosis

If your provider prescribes Strattera or another non-stimulant:

Electronic prescription: Your prescription will be sent electronically to your preferred pharmacy, typically within hours.

Medication education: Your provider will explain how to take the medication, what side effects to watch for, and when to expect results.

Follow-up scheduling: You’ll typically have a check-in appointment in 3–4 weeks to assess how the medication is working and make any needed dose adjustments.

Ongoing monitoring: Non-stimulant treatment usually involves periodic follow-ups (monthly initially, then every 2–3 months once stable) to monitor effectiveness and side effects.

Common Questions and Misconceptions

‘Can I really get ADHD medication without an in-person visit?’

Yes—for non-stimulant medications like Strattera, federal law has never required an in-person visit. A comprehensive telehealth video evaluation meets the standard of care. For stimulants, it’s currently allowed under temporary DEA rules through the end of 2025, though some states (like New York) have reimposed in-person requirements.

‘Isn’t telehealth ADHD prescribing just a ‘pill mill’?’

Legitimate telehealth providers follow the same diagnostic standards and prescribing practices as in-person care. The high-profile cases you may have read about (Cerebral, Done) involved companies that allegedly didn’t follow proper protocols—and they faced serious regulatory consequences.

Reputable platforms conduct thorough evaluations, require regular follow-ups, coordinate with other providers when needed, and have safeguards in place to prevent inappropriate prescribing. If a telehealth service guarantees medication or doesn’t require a detailed assessment, that’s a red flag.

‘Non-stimulants don’t work as well as stimulants’

While stimulants are often first-line treatment and work for about 70–80% of people with ADHD, non-stimulants can be highly effective—especially for certain patients. Research shows Strattera significantly improves ADHD symptoms in 50–60% of patients, with the added benefits of 24-hour coverage, no abuse potential, and potentially fewer side effects like sleep disruption or appetite loss.

For people who can’t take stimulants or who experience problematic side effects, non-stimulants offer an excellent alternative. The ‘best’ medication is the one that works for you with tolerable side effects.

‘My pharmacy won’t fill a telehealth prescription’

This is generally a myth. Pharmacies regularly fill electronic prescriptions from telehealth providers—they’re indistinguishable from in-person prescriptions in the pharmacy’s system.

Some pharmacies did increase scrutiny of certain telehealth prescriptions in 2023 during the controversies around online ADHD services. Using a reputable telehealth platform and maintaining a consistent relationship with one pharmacy helps avoid any issues. Strattera prescriptions typically face no special scrutiny since it’s not a controlled substance.

‘I’ll have to stay on telehealth forever—can I switch to in-person later?’

Absolutely. Telehealth is flexible. Many people start treatment via telehealth for convenience, then transition to an in-person provider, or vice versa. Your telehealth provider can coordinate care with a local physician and transfer your records when you’re ready to make a change.

Key Considerations for Safe Telehealth ADHD Treatment

Be Honest and Thorough

Your provider can’t physically examine you, so they rely heavily on the information you provide. Be completely honest about:

• Your symptoms and their severity
• Any history of substance use or abuse
• Other medical conditions
• Previous mental health treatment
• Current medications and supplements

Withholding information doesn’t just risk getting inappropriate treatment—it can be dangerous.

Attend Follow-Up Appointments

ADHD medication management isn’t ‘set it and forget it.’ Especially when starting Strattera, you’ll need regular check-ins to:

• Monitor how the medication is working
• Adjust dosage if needed
• Watch for side effects
• Assess overall functioning and quality of life

Missing follow-ups may result in your provider discontinuing medication until you can be properly evaluated.

Understand Your State’s Rules

While your telehealth provider should handle compliance, knowing your state’s requirements helps you understand what to expect. For example:

• Alabama patients shouldn’t be surprised if their provider mentions needing an in-person visit within 12 months for ongoing care
• New York patients seeking stimulants need to know they’ll require an initial in-person evaluation
• Texas patients seeing an NP should understand that provider may not be able to prescribe stimulants

Keep Your Provider Informed

Report any changes in your health status, new medications, or significant life changes (moving states, becoming pregnant, new jobs that might affect treatment needs). This allows your provider to adjust your treatment plan appropriately.

Have a Backup Plan

Given the evolving regulatory landscape, discuss with your provider what would happen if telehealth rules change. For instance:

• Do they have in-person locations you could visit if needed?
• Can they coordinate with a local provider?
• What’s the plan if you need to transition care?

Being proactive ensures continuity of treatment even if regulations shift.

The Future of Telehealth ADHD Treatment

Regulatory Trends

Most experts expect telehealth to remain a permanent fixture of ADHD treatment, though the exact rules may evolve:

More states are liberalizing telehealth laws: We’ve seen this with New Hampshire in 2025 and California’s proposed legislation. The trend is toward recognizing telehealth as equivalent to in-person care.

Increased safeguards: At the same time, states are implementing stronger prescription monitoring and requiring e-prescribing to prevent abuse while maintaining access.

Potential federal framework: The DEA’s proposed ‘special registration’ for telehealth prescribers could create a permanent pathway for controlled substance prescribing with appropriate safeguards.

Technology Integration

Telehealth platforms are increasingly incorporating:

• Integration with PDMP databases for real-time monitoring
• Secure coordination with pharmacies and other providers
• Remote patient monitoring for medication adherence and side effects
• AI-assisted documentation (while maintaining physician oversight)

Expanding Access

Telehealth has proven particularly valuable for:

• Rural communities with limited access to psychiatrists
• People with transportation barriers
• Those who feel more comfortable discussing mental health concerns from home
• Patients who need flexible scheduling due to work or family obligations

As regulations stabilize and best practices emerge, telehealth will likely become an increasingly standard way to access ADHD treatment—especially for non-controlled medications.

Taking the Next Step

If you’re struggling with ADHD symptoms and wondering whether telehealth treatment might be right for you, here’s what to do:

1. Assess your symptoms: Complete a reputable ADHD screening tool online to see if your symptoms align with ADHD criteria. This isn’t a diagnosis, but it can help you decide whether to seek professional evaluation.

2. Research telehealth providers: Look for platforms with:

• Licensed clinicians in your state
• Transparent pricing and insurance acceptance
• Comprehensive evaluation processes (not ‘quick scripts’)
• Positive patient reviews
• Clear policies on treatment and follow-up

3. Check your insurance coverage: Many insurance plans now cover telehealth for mental health services at the same rate as in-person care. Verify your coverage and any copays.

4. Prepare for your evaluation: Gather relevant medical records, be ready to discuss your symptoms in detail, and set aside adequate time for a thorough appointment (45–60 minutes).

5. Set realistic expectations: Remember that ADHD treatment is a process, not a quick fix. If you’re prescribed Strattera, it may take 4–6 weeks to feel the full benefits. Be patient and maintain open communication with your provider.

Conclusion: Accessible, Quality Care is Within Reach

The landscape of ADHD treatment has evolved dramatically, and telehealth has opened doors for millions of people who previously struggled to access care. For non-stimulant medications like Strattera, the path is clear: comprehensive telehealth evaluation can lead to effective treatment without the burden of in-person visits.

While federal and state regulations continue to develop—particularly around stimulant medications—the core principle remains: you deserve accessible, high-quality ADHD treatment that fits your life and meets your needs.

Whether you’re newly considering an ADHD diagnosis or you’ve been managing symptoms for years, telehealth offers a convenient, legitimate pathway to evidence-based care. By choosing a reputable provider, being an active participant in your treatment, and staying informed about your options, you can successfully manage ADHD and improve your quality of life.

At Klarity Health, we’re committed to making that journey as straightforward as possible—connecting you with experienced providers, accepting both insurance and cash pay, and supporting you every step of the way.

Ready to take the first step toward better ADHD management? Schedule your confidential evaluation with a licensed provider today.

Sources

1. DEA ‘Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescribing Controlled Substances’ – Fierce Healthcare, November 2024. www.fiercehealthcare.com

2. ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions’ – Sheppard Mullin Healthcare Law Blog, National Law Review, August 15, 2025. www.sheppardhealthlaw.com

3. ‘The Telehealth Compliance Trap: DEA’s Controlled Substance Rules’ – RxAgent Blog, October 2025. www.rxagent.co

4. ‘Is Strattera a Controlled Substance?’ – Medical News Today, January 14, 2025. www.medicalnewstoday.com

5. ‘Can an NP Prescribe Schedule 2 in Texas?’ – SingleAim Health, December 9, 2025. www.singleaimhealth.com

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment